Table 1

 Baseline characteristics of patient collective with regard to ISR development within the lesion and progression of other untreated plaques

AllISRNo ISRProgressNo progress
ACE, angiotensin converting enzyme; ACS, acute coronary syndrome; AT1, angiotensin type 1; CAD, coronary artery disease; GP, glycoprotein; ISR, in-stent restenosis; MI, myocardial infarction.
*p<0.001, ISR v no ISR group; **p<0.05, progress v no progress group.
Number of patients (%)219 (100%)61 (28%)158 (72%)15 (7%)204 (93%)
Age (years)63 (10)63 (11)64 (10)63 (9)63 (10)
Male sex173 (79%)48 (78%)126 (80%)13 (87%)157 (77%)
ACS118 (54%)39 (64%)71 (45%)9 (60%)108 (53%)
Acute MI53 (24%)16 (26%)35 (22%)4 (27%)47 (23%)
Previous MI61 (28%)19 (31%)41 (26%)3 (20%)59 (29%)
Risk factors
Diabetes42 (19%)17 (28%)*17 (11%)*3 (20%)37 (18%)
Hypertension136 (62%)41 (67%)92 (58%)10 (67%)126 (62%)
Hypercholesterolaemia83 (38%)27 (44%)51 (32%)8 (53%)73 (36%)
Current smoker94 (43%)30 (49%)60 (38%)12 (80%)**80 (39%)**
Family history of CAD68 (31%)21 (34%)43 (27%)4 (27%)63 (31%)
Medication
Aspirin219 (100%)61 (100%)158 (100%)15 (100%)204 (100%)
Clopidogrel219 (100%)61 (100%)158 (100%)15 (100%)204 (100%)
Nitrate96 (44%)24 (39%)76 (48%)5 (33%)92 (45%)
β Blocker99 (45%)34 (56%)57 (36%)10 (67%)96 (47%)
ACE inhibitor99 (45%)35 (57%)54 (34%)8 (53%)106 (52%)
AT1 antagonist18 (8%)4 (7%)16 (10%)1 (7%)16 (8%)
Calcium antagonist28 (13%)13 (21%)11 (7%)1 (7%)29 (14%)
Statin99 (45%)35 (57%)55 (35%)10 (67%)102 (50%)
GP IIb/IIIa antagonist55 (25%)15 (25%)36 (23%)4 (27%)53 (26%)